Publications

1. Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C, Herzel H, Tsang AH, Kawakami N, Leliavski A, Uhl O, Yao L, Sander LE, Chen C-S, Kraus K, de Juan A, Hergenhan SM, Ehlers M, Koletzko B, Haas R, Solbach W, Oster H, and Scheiermann C. Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses. Immunity 2017 46(1):120-132.

doi: 10.1016/j.immuni.2016.12.011.

PMID: 28087238

2. Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, Weiss K-H, Liaskou E, Vesterhus M, Karlsen TH, Mindorf S, Schemmer P, Bär F, Teegen B, Schröder T, Ehlers M, Hammers CM, Komorowski L, Lehnert H, Fellermann K, Derer S, Hov JR, and Sina C. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 2017 66(1):137-144.

doi: 10.1136/gutjnl-2016-311739.

PMID: 27406039

3. Strait RT, Posgai MT, Mahler A, Barasa N, Jacob CO, Köhl J, Ehlers M, Stringer K, Shanmukappa SK, Witte D, Hossain MM, Khodoun M, Herr AB, and Finkelman FD. IgG1 protects against renal disease in a mouse model of cryoglobulinemia. Nature 2015; 517(7535):501-504.

doi: 10.1038/nature13868.

PMID: 25363774

4. Schwedler C, Kaup M, Petzold D, Hoppe B, Braicu EI, Sehouli J, Ehlers M, Berger M, Tauber R, and Blanchard V. Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulin G N-glycans of ovarian cancer patients. Electrophoresis 2014; 35(7):1025-1031.

PMID: 24812685

5. Collin M, and Ehlers M. The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. Exp Dermatol 2013; 22(8):511-514.

doi: 10.1111/exd.12171. Review.

PMID: 23808883

6. Hess C, Winkler A, Lorenz AK, Holecska V, Blanchard V, Eiglmeier S, Schoen A-L, Bitterling J, Stoehr AD, Petzold D, Schommartz T, Mertes MMM, Schoen CT, Tiburzy B, Herrmann A, Köhl J, Manz RA, Madaio MP, Berger M, Wardemann H, and Ehlers M. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J Clinical Invest 2013; 123(9):3788–3796.

doi: 10.1172/JCI65938.

PMID: 23979161

7. Winkler A, Berger M, and Ehlers M. Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies [v1; ref status: indexed, http://f1000r.es/1fg]. F1000Research 2013; 2:169

doi: 10.12688/f1000research.2-169.v1.

PMID: 24358898

8. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, McDonald JU, Orr S, Berger M, Petzold D, Blanchard V, Winkler A, Hess C, Reid DM, Majoul IV, Strait RT, Harris NL, Köhl G, Wollin L, Ludwig R, Zillikens D, Nimmerjahn F, Finkelman FD, Brown GD, Ehlers M, and Köhl J. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nature Medicine 2012; 18(9):1401-1406.

PMID: 22922409

9. Ehlers M. Glycosylation-dependent effector function of IgG antibodies. Z. Rheumatol. 2012; 71:798-800.

doi: 10.1007/s00393-012-1007-7. Review

PMID:23138557

10. Oefner CM, Winkler A, Hess C, Lorenz, AK, Holecska V, Huxdorf M, Schommartz T, Petzold D, Bitterling J, Schoen A-L, Stoehr AD, Vu Van D, Darcan-Nikolaisen Y, Blanchard V, Schmudde I, Laumonnier Y, Ströver HA, Hegazy AN, Eiglmeier S, Schoen CT, Mertes MMM, Loddenkemper C, Löhning M, König P, Petersen A, Luger EO, Collin M, Köhl J, Hutloff A, Hamelmann E, Berger M, Wardemann H, and Ehlers M. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J Allergy and Clinic Immunol 2012; 129(6):1647-1655.

doi: 10.1016/j.jaci.2012.02.037.

PMID: 22502800

11. Stoehr AD, Schoen CT, Mertes MMM, Eiglmeier S, Holecska V, Lorenz AK, Schommartz T, Schoen A-L, Hess C, Winkler A, Wardemann H, and Ehlers M. TLR9 in peritoneal B-1b cells is essential for production of protective self-reactive IgM to control Th17 cells and severe autoimmunity. J Immunol 2011; 187:2953-2965.

doi: 10.4049/jimmunol.1003340.

PMID: 21859955

12. Tiller T, Kofer J, Kreschel C, Busse CE, Riebel S, Wickert S, Oden F, Mertes MMM, Ehlers M, and Wardemann H. Development of self-reactive germinal cener B cells and plasma cells in autoimmune FcgammaRIIB-deficient mice. J Exp Med 2010; 207:2767-2778.

doi: 10.1084/jem.20100171.

PMID: 21078890

13. Zamisch M, Tian L, Grenningloh R, Xiong Y, Wildt KF, Ehlers M, Ho-C, and Bosselut R. The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus. J Exp Med 2009; 206:2685-2699.

doi: 10.1084/jem.20092024.

PMID: 19917777

14. Fischer M, and Ehlers M. Toll-like receptors in autoimmunity. The Year in Immunology 2008, Ann N Y Acad Sci 2008; 1143:21-34.

doi: 10.1196/annals.1443.012. Review.

PMID: 19076342

15. Ehlers M, and Ravetch JV. Opposing effects of Toll-like receptor signals induce autoimmunity or tolerance. Trends in Immunol 2007; 28:74-79.

Review.

PMID: 17197239

16. Wildt, KF, Sun G, Grueter B, Fischer M, Zanisch M, Ehlers M, and Bosselut R. The transcription factor Zbtb7b promotes CD4 expression by antagonizing Runx-mediated activation of the CD4 silencer. J Immunol 2007; 179:4405-4414.

PMID: 17878336

17. Ehlers M, Fukuyama H, McGaha H, Aderem A, and Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203:553-561.

PMID: 16492804

18. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, Steinman RM, Ravetch JV, and Dhodapkar MV. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A 2005; 102:2910-2915.

PMID: 15703291

19. Grueter B, Petter M, Laule-Kilian K, Egawa T, Aldrian CJ, Wuerch A, Ludwig Y, Fukuyama H, Wardemann H, Waldschuetz R, Moeroey T, Taniuchi I, Steimle V, Littman DR, and Ehlers M. Runx3 regulates integrin alphaE/CD103 and CD4 expression during development of CD4-/CD8+ T cells. J Immunol 2005; 175:1694-1705.

PMID: 16034110

20. Ehlers M, Laule-Kilian K, Petter M, Aldrian CJ, Grüter B, Würch A, Yoshida N, Watanabe T, Satake M, and Steimle V. Morpholino antisense oligonucleotide-mediated gene knockdown during thymocyte development reveals role for Runx3 transcription factor in CD4 silencing during development of CD4-/CD8+ thymocytes. J Immunol 2003; 171:3594-3604.

PMID: 14500656

21. Ehlers M, Grötzinger J, Fischer M, Klaasse Bos H, Brakenhoff, JPJ, and Rose-John S. Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation. J Interferon Cytokine Res 1996; 16:569-576.

PMID: 8877726

22. Vollmer P, Peters M, Ehlers M, Yagame H, Matsuba T, Kondo M, Yasukawa K, Meyer zum Büschenfelde K-H, and Rose-John S. Yeast expression of the cytokine receptor domain of the soluble interleukin-6-receptor. J Immunol Methods 1996; 199, 47-54.

PMID: 8960097

23. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Meyer zum Büschenfelde K.-H, and Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996; 183:1399-1406.

PMID: 8666898

24. Ehlers M, de Hon FD, Klaasse Bos H, Horsten U, Kurapkat G, Schmitz van De Leur H, Grötzinger J, Wollmer A, Brakenhoff JPJ, and Rose-John S. Combining two mutations of human Interleukin-6 that affect gp130 activation results in a potent Interleukin-6 receptor antagonist on human myeloma cells. J Biol Chem 1995; 270:8158-8163.

PMID: 7713920

25. Ehlers M, Grötzinger J, de Hon FD, Müllberg J, Brakenhoff JPJ, Wollmer A, and Rose-John S. Residues 77-95 of the human interleukin-6 protein are responsible for receptor binding and residues 41-56 for signal transduction. Ann NY Acad Sci 1995; 762:400-402.

PMID: 7668541

26. Rose-John S, Ehlers M, Grötzinger J, and Müllberg J. The soluble interleukin-6 receptor. Ann NY Acad Sci 1995; 762:207-220.

PMID: 7668529

27. de Hon FD, ten Boekel E, Herrmann J, Clement C, Ehlers M, Taga T, Yasukawa K, Ohsugi Y, Kishimoto T, Rose-John S, Wijdenes J, Kastelein R, Aarden LA, and Brakenhoff JPJ. Functional distinction of two regions of human interleukin-6 important for signal transduction via gp130. Cytokine 1995; 7:398-407.

PMID: 7578977

28. de Hon FD, Ehlers M, Rose-John S, Ebeling SB, Klaasse Bos H, Aarden LA, and Brakenhoff JPJ. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J Exp Med 1994; 180:2395-2400.

PMID: 7964514

29. Ehlers M, Grötzinger J, de Hon FD, Müllberg J, Brakenhoff JPJ, Liu J, Wollmer A, and Rose-John S. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol 1994; 153:1744-1753.

PMID: 7519211